Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The share is getting closer to its long-term support in weekly data, at CAD 0.12, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the CAD 0.12 support.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 0.17 CAD
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
PROMIS NEUROSCIENCES, INC.-23.53%28
-
GILEAD SCIENCES, INC.-7.34%75 487
REGENERON PHARMACEUTICALS52.44%60 234
VERTEX PHARMACEUTICALS-3.46%55 058
WUXI APPTEC CO., LTD.64.60%39 515
BEIGENE, LTD.82.54%27 421
GENMAB A/S50.39%23 222
BIONTECH SE158.91%20 893
HUALAN BIOLOGICAL ENGINEERI..110.85%15 640
ARGENX SE53.06%12 350
MYOKARDIA, INC.205.14%11 859
-
SAREPTA THERAPEUTICS, INC.6.37%10 776
NEUROCRINE BIOSCIENCES, INC..-10.86%8 936
ASCENDIS PHARMA A/S12.16%8 302
MIRATI THERAPEUTICS, INC.43.52%8 237
BIOCON LIMITED49.68%7 073
More Results
Financials
Sales 2020 - - -
Net income 2020 -6,80 M -5,17 M -5,17 M
Net Debt 2020 - - -
P/E ratio 2020 -6,33x
Yield 2020 -
Capitalization 36,2 M 27,6 M 27,6 M
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees -
Free-Float 90,1%
Upcoming event on PROMIS NEUROSCIENCES, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating -
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability -
P/E ratio -
Potential
Yield -
Consensus -
7 days EPS revision -
4 months EPS revision -
1 year EPS revision -
4 months Revenue revision -
1 year Revenue revision -
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes